Summit Therapeutics launches at-the-market equity program for up to $380 million
SMMT•At-the-market equity program
Summit Therapeutics entered an at-the-market equity distribution agreement with J.P. Morgan Securities to sell up to $380 million of common stock.
Sales can be made from time to time at prevailing market prices or negotiated prices, with the company retaining discretion over timing and size.
Commission and registration statement
J.P. Morgan will receive a commission of up to 3% of gross sales.
The program uses the company’s effective Form S-3 registration statement filed June 9, 2026, with a prospectus supplement dated July 23, 2026.
